RGMA as a Radioligand Therapy Target
RGMA, repulsive guidance molecule BMP co-receptor a, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, RGMA staining is highest in neuroendocrine tumors (75% of samples positive), gastric cancer (100% of samples positive) and colorectal cancer (100% of samples positive). Evidence on whether RGMA internalizes is mixed. Clinical status: Clinical-stage (up to phase 2, any modality).
Is RGMA a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in neuroendocrine tumors, 75% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
RGMA expression in cancer
Protein expression of RGMA across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Neuroendocrine Tumors | 0.67 | High | 75% |
| Gastric Cancer | 0.64 | High | 100% |
| Colorectal Cancer | 0.64 | High | 100% |
| Pancreatic Cancer | 0.64 | High | 100% |
| Testicular Cancer | 0.64 | High | 100% |
| Liver Cancer | 0.63 | High | 100% |
| Cervical Cancer | 0.53 | High | 92% |
| Kidney Cancer | 0.53 | High | 83% |
| Ovarian Cancer | 0.50 | Medium | 83% |
| Bladder Cancer | 0.48 | Medium | 91% |
| Breast Cancer | 0.42 | Medium | 91% |
| Head and Neck Cancer | 0.42 | Medium | 75% |
| Thyroid Cancer | 0.42 | Medium | 75% |
| Melanoma | 0.42 | Medium | 67% |
| Prostate Cancer | 0.40 | Medium | 60% |
| Endometrial Cancer | 0.36 | Medium | 82% |
| Glioma | 0.31 | Medium | 50% |
| Lymphoma | 0.28 | Medium | 58% |
| Skin Cancer | 0.27 | Medium | 64% |
| Lung Cancer | 0.27 | Medium | 60% |
Is RGMA internalized?
Uncertain. Insufficient literature found.
RGMA clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for RGMA yet. Search ClinicalTrials.gov for RGMA trials.
RGMA normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See RGMA in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
RGMA gene essentiality (DepMap)
CRISPR knockout effect across 1256 cancer cell lines: 0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related neuroendocrine tumors radioligand targets
HER3 (ERBB3) · c-MET (MET) · SSTR2 · STEAP2 · EPCAM · ITGB6 · KIT · FAP
See all radioligand therapy targets in neuroendocrine tumors.
See how RGMA ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.